Investigational drug · Phase 2
IL-2
Also called: MDNA11, Interleukin-2 -albumin
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
1,090
Any phase or sponsor naming "IL-2"
First trial start
2021
Aug 27, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IL-2", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Unresectable Solid Tumor
- Clear Cell Renal Cell Carcinoma
- Triple Negative Breast Cancer
- Non-Small Cell Lung Cancer Squamous
- Non-Small Cell Lung Cancer Non-squamous
- Colorectal Cancer (MSI-H)
- Gastric Cancer
- Cervical Cancer
- Basal Cell Carcinoma
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Kidney cancer (renal cell carcinoma) · Stomach and esophageal cancer · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "IL-2" as an intervention, largest first.
- An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral TherapyPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00004978 · 4,150 participants · Start Mar 2000 · Primary completion Nov 2008
Drug: Recombinant interleukin-2 (rIL-2) · For: HIV Infections
Sites: Los Angeles, California; Mill Valley, California; Oakland, California · 248 sites in all
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
- Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid LeukemiaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00004128 · 2,000 participants (planned) · Start Sep 1999 · Primary completion Jan 2008
Drug: aldesleukin; filgrastim and 5 more · For: Leukemia
- Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)Pivotal-lookingCompleted
University of MinnesotaAcademic, hospital or other
NCT00013611 · 1,695 participants · Start Mar 2001 · Primary completion Jan 2007
Drug: Proleukin · For: HIV Infection
Sites: Bethesda, Maryland
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With NeuroblastomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00026312 · 1,449 participants · Start Oct 26, 2001 · Primary completion Jan 12, 2012
Drug: Aldesleukin; Dinutuximab and 2 more · For: Localized Resectable Neuroblastoma; Localized Unresectable Neuroblastoma; Recurrent Neuroblastoma and 3 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 197 sites in all
- Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic MelanomaPivotal-lookingActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT00338377 · 1,230 participants · Start Feb 1, 2006 · Primary completion Feb 28, 2030
Drug: Dendritic Cell Immunization; Cyclophosphamide and 6 more · For: Melanoma
Sites: Houston, Texas
- A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07217301 · 1,200 participants (planned) · Start Nov 26, 2025 · Primary completion Nov 1, 2028
Drug: TAK-928; Control Arm · For: IO Resistant Squamous and Nonsquamous NSCLC
Sites: Jonesboro, Arkansas; Fair Oaks, California; Fountain Valley, California · 50 sites in all
- DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in TreatingPivotal-lookingNot yet recruiting
The First People's Hospital of ChangzhouAcademic, hospital or other
NCT02487550 · 1,200 participants (planned) · Start Aug 2015 · Primary completion Jul 2028
Drug: DC-CIK; IL-2/IFN-α · For: Renal Neoplasma
- A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2Pivotal-lookingStatus unknown
Beijing Chest HospitalAcademic, hospital or other
NCT04766307 · 1,100 participants (planned) · Start Jul 20, 2016 · Primary completion Dec 31, 2021
Drug: Interleukin-2 · For: Tuberculosis, Pulmonary
Sites: Fuyang, China; Fuzhou, China; Shenzhen, China · 16 sites in all
- Treatment of CIK for Patients With Refractory Non-Hodgkin LymphomaPivotal-lookingNot yet recruiting
The First People's Hospital of ChangzhouAcademic, hospital or other
NCT02497898 · 1,000 participants (planned) · Start Jul 2015 · Primary completion Jul 2038
Drug: Cytokine-induced killer cells (CIK) · For: Lymphoma, Non-Hodgkin
Newest research
PubMed records naming it or its code names, newest first.
- Molecularly nanoengineered dendritic cells for tumor-specific antigen capture and sono-activatable cytokine-mediated immunotherapy.
Yu N, Lu S, Xiao B, et al. · Biomaterials 2027
- ShenqiYichang decoction enhances colorectal cancer immune efficacy via IDO1 mediated reduction of Treg infiltration.
Yang Y, Li L, Fang Y, et al. · J Ethnopharmacol 2027
- Predicted mechanisms of Huaier in hepatocellular carcinoma therapy via IL-2/PI3K-Akt immunomodulation: An integrated multi-method study.
Li H, Liu X, Song Y, et al. · J Ethnopharmacol 2027
- Beyond pyroptosis: Non-lytic functions of GSDMD in tumor immunity and cancer immunotherapy.
Wang X, Du Q, Wu J, et al. · Biochim Biophys Acta Mol Basis Dis 2027
- Probiotics alleviate heat stress-induced uterine inflammation, reproductive hormone disruption and fetal growth restriction in mice.
Zhou H, Chen M, Wang X, et al. · Theriogenology 2027
- Simultaneous solubility-enhancing domain removal and target purification using the Npu split intein.
Mayone S, Napier SK, Adomanis R, et al. · Protein Expr Purif 2027
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.